EP 3209147 A1 20170830 - COMPOSITION COMPRISING PLANT PROTEINS AND USE FOR PREVENTING METABOLIC AND CARDIOVASCULAR PATHOLOGICAL CONDITIONS ASSOCIATED WITH CARDIOMETABOLIC RISK IN PARTICULAR WITH HYPERGLYCAEMIA
Title (en)
COMPOSITION COMPRISING PLANT PROTEINS AND USE FOR PREVENTING METABOLIC AND CARDIOVASCULAR PATHOLOGICAL CONDITIONS ASSOCIATED WITH CARDIOMETABOLIC RISK IN PARTICULAR WITH HYPERGLYCAEMIA
Title (de)
ZUSAMMENSETZUNG MIT PFLANZLICHEN PROTEINEN UND VERWENDUNG ZUR VERHINDERUNG METABOLISCHER UND KARDIOVASKULÄRER KRANKHEITSZUSTÄNDE IM ZUSAMMENHANG MIT KARDIOMETABOLISCHEN RISIKEN, INSBESONDERE BEI HYPERGLYKÄMIE
Title (fr)
COMPOSITION COMPRENANT DES PROTEINES VEGETALES ET UTILISATION POUR LA PREVENTION DES PATHOLOGIES METABOLIQUES ET CARDIOVASCULAIRES ASSOCIEES AU RISQUE CARDIOMETABOLIQUE EN PARTICULIER AVEC HYPERGLYCEMIE
Publication
Application
Priority
- FR 1460157 A 20141022
- EP 2015074540 W 20151022
Abstract (en)
[origin: WO2016062830A1] The subject matter of the invention is a composition suitable for oral administration in humans, comprising at least one plant protein chosen from pea proteins, rice proteins or a mixture of pea protein(s) and rice protein(s), and: - at least one protein of animal origin chosen from calcium caseinate, whey proteins, or a mixture of the two, and/or - at least one free amino acid chosen from leucine, glutamine, isoleucine, valine, tryptophan or plant 5HTP, lysine, threonine, arginine and taurine, or a mixture of at least two of these amino acids, and/or - at least one micronutrient chosen from vitamin D, vitamin B6, vitamin B9, vitamin E, calcium from milk, marine magnesium, zinc and chromium, or a mixture of at least two of these micronutrients, and/or - at least one anti-inflammatory and/or antioxidant compound of plant origin chosen from omega 3 fatty acid in ALA form, purified EPA, protectin in PD1 or PDX form, and curcumin, or a mixture of at least two of these anti-inflammatory compounds of plant origin. The invention is also directed towards the use thereof for preventing cardiometabolic risk.
IPC 8 full level
A23L 33/15 (2016.01); A23L 33/10 (2016.01); A23L 33/16 (2016.01); A23L 33/17 (2016.01); A61P 3/00 (2006.01)
CPC (source: EP US)
A23L 2/52 (2013.01 - EP US); A23L 2/66 (2013.01 - EP US); A23L 33/10 (2016.07 - EP US); A23L 33/12 (2016.07 - EP US); A23L 33/15 (2016.07 - EP US); A23L 33/155 (2016.07 - EP US); A23L 33/16 (2016.07 - EP US); A23L 33/17 (2016.07 - EP US); A23L 33/175 (2016.07 - EP US); A23L 33/185 (2016.07 - EP US); A23L 33/19 (2016.07 - EP US); A61K 31/121 (2013.01 - EP US); A61K 31/185 (2013.01 - EP US); A61K 31/198 (2013.01 - EP US); A61K 31/202 (2013.01 - EP US); A61K 31/405 (2013.01 - EP US); A61K 38/168 (2013.01 - EP US); A61K 38/1709 (2013.01 - EP US); A61K 38/38 (2013.01 - EP US); A61K 47/02 (2013.01 - US); A61K 47/10 (2013.01 - US); A61K 47/22 (2013.01 - US); A61K 47/24 (2013.01 - US); A61P 3/00 (2017.12 - EP); A23V 2002/00 (2013.01 - EP US)
Citation (search report)
See references of WO 2016062830A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2016062830 A1 20160428; EP 3209147 A1 20170830; FR 3027491 A1 20160429; FR 3027491 B1 20171229; US 2016114002 A1 20160428
DOCDB simple family (application)
EP 2015074540 W 20151022; EP 15797865 A 20151022; FR 1460157 A 20141022; US 201414549709 A 20141121